Immunotherapy drug Keytruda received FDA approval and showed benefit for treatment of colorectal cancer
https://www.facingourrisk.org/XRAY/keytruda-effective-in-treating-colorectal-cancer
Full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer
In June 2020, the FDA approved Keytruda (pembrolizumab) as an initial therapy for advanced colorectal cancer. This approval was based on the results from the KEYNOTE-177 study. In this study, Keytruda was more successful than chemotherapy in delaying progression of certain types of colorectal cancers. (11/25/20)
Questions To Ask Your Health Care Provider
- What are the best drug options for treating my colorectal cancer?
- What are the side effects of my treatment drugs?
- Which biomarkers was my cancer tested for? What were the results?
- Is my cancer due to microsatellite instability or mismatch repair deficiency?
- Can you provide a copy of my biomarker test results?
- Do I meet criteria for genetic counseling and testing for an inherited mutation?
- Can you refer me to a genetic counselor?
- Should I consider a clinical trial?
Open Clinical Trials
The following studies enroll people with advanced colorectal cancer.
- NCT03607890: Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor. This study evaluates the safety, effectiveness and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors that were resistant to prior PD-(L)1 therapy.
- NCT05253651: Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting. This study evaluates whether the drug Tukysa (tucatinib) combined with other cancer drugs is more effective than the standard-of-care treatment in people with HER2-positive colorectal cancer.
- NCT02997228: Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study). The effort compares the effectiveness of combining chemotherapy and immunotherapy with an immunotherapy drug alone.
- NCT04008030: Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer. This study compares the combination of immunotherapy agents nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients who have MSI-H or dMMR metastatic colorectal cancer versus with nivolumab alone or chemotherapy alone.
Several other clinical trials for patients with colorectal cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.